Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Now Viewing

EP: 1.Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

EP: 2.ASCO 2024: Key Findings of the LAURA Trial on7:19 Osimertinib for EGFR-Mutated NSCLC

EP: 3.Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

EP: 4.Insights from the TROPION-Lung05 Trial at ASCO 2024

EP: 5.Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

EP: 6.ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Related Videos

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).